???jsp.layout.hku.browse.grant_fundingyear???

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中 >>

Browse by Funding Year 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013

Showing results 12 to 19 of 19

< previous

	Project Title	Principal Investigator	Year
12	Phase 2, open-label single arm study of the efficacy and safety of PF 02341066 in patients with advanced non-small cell lung cancer (NSCLC) harboring a translocation or inversion involving the anaplastic lymphoma kinase (ALK) gene locus	Ho, James Chung Man	2010/2011
13	Phase 3, randomized, open-label study of the efficacy and safety of PF-02341066 versus standard of care chemotherapy (pemetrexed or docetaxel) in patients with advanced nonsmall cell lung cancer (NSCLC) harbouring a translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene locus	Ho, James Chung Man	2010/2011
14	A multicenter randomised double blind placebo controlled study of AMG785 in skeletally mature adults with a fresh unilateral tibial diaphyseal fracture status post definitive fracture fixation with an intramedullary nail	Leung, Frankie Ka Li	2010/2011
15	Randomized controlled trial of S-1 versus docetaxel in patients with non-small cell lung cancer who have received a platinum-based treatment	Ho, James Chung Man	2010/2011
16	A Randomized, Double-Blind, Phase 2 Study of erlotinib (Tarcevar) in combination with OSI 906 or placebo in Chemonaive Patients with Advanced NSCLC with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene	Ho, James Chung Man	2010/2011
17	Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects with Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC)	Ho, James Chung Man	2010/2011
18	Study of immunopathogenesis of multiple sclerosis and neuromyelitis optica	Chan, Koon Ho	2011/2012
19	A Phase III Randomised, Double blind, Placebo controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of continuing IRESSATM 250 mg in addition to Chemotherapy versus Chemotherapy alone in Patients who have Epidermal Growth Factor Receptor (EGFR)Mutation Positive Locally advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and have progressed on First Line IRESSATM	Ho, James Chung Man	2011/2012

< previous